GlassScriptPhysician profile
Mohammed S Qayyum
NPI 1679666994
$132,261.91
in general payments reported to CMS, 2019-2025
38 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $40K · 2021: $38K · 2022: $11K · 2023: $3,070 · 2024: $1,717 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,029 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,029.00 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $104,000.00 | 2019-2021 | |
| Boston Scientific Corporation | $9,182.90 | 2022-2025 | Watchman Flx |
| Acist Medical Systems, INC. | $3,236.91 | 2019-2023 | |
| Abbott Laboratories | $3,046.05 | 2019-2024 | Diamondback Coronary, Optis, Dragonfly Opstar |
| Biotronik INC. | $1,868.32 | 2019-2025 | Biomonitor, Orsiro Mission, Edora 8 Dr-T |
| Actelion Pharmaceuticals US, INC. | $1,615.75 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Cardiovascular Systems INC. | $1,346.64 | 2019-2022 | |
| Shockwave Medical, INC | $1,242.52 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $1,034.40 | 2019-2020 | |
| Amgen INC. | $858.92 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $669.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $632.25 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $351.11 | 2020-2024 | Brilinta |
| Pfizer INC. | $349.61 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $349.57 | 2019-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $330.54 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Regeneron Healthcare Solutions, INC. | $293.46 | 2019-2024 | Evkeeza |
| Esperion Therapeutics, INC. | $285.32 | 2020-2025 | Nexletol |
| Abiomed | $263.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $251.46 | 2022-2025 | Eliquis, Camzyos |
| Portola Pharmaceuticals, LLC | $212.07 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $202.15 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $115.95 | 2020-2021 | |
| Terumo Medical Corporation | $99.90 | 2019 | |
| Philips North America LLC | $62.79 | 2019-2021 | |
| Baxter Healthcare | $48.94 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Veryan Medical Incorporated | $41.89 | 2022 | |
| Merck Sharp & Dohme LLC | $39.85 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $35.33 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $34.03 | 2024 | Assure Wcd |
| Penumbra, INC. | $29.00 | 2024 | Penumbra System |
| Medtronic, INC. | $25.24 | 2024 | Micra |
| Cardiva Medical, INC. | $21.16 | 2022 | |
| Heartflow, INC. | $20.76 | 2024 | |
| Gilead Sciences, INC. | $20.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.29 | 2023 | Jardiance |
| Agepha Pharma Fz LLC | $14.42 | 2025 | Lodoco |
| Infobionic, INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Qayyum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.